IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that it supports Larry Ellison’s announcement about Raymond Moore’s resignation as CEO of Indian Wells. Masimo has been a Premier Sponsor of the BNP Paribas Open and presenting sponsor for the McEnroe Challenge for Charity for several years.
“Women’s tennis is just as fun and exciting to watch as the men’s game. Mr. Moore’s disturbing comments regarding WTA and female tennis players shocked us,” said Joe Kiani, Founder and CEO of Masimo. “BNP Paribas Open Tennis is the best tennis I have seen. With the swift move to disassociate this great event from Mr. Moore’s comments, we are once again proud to be associated with this great event. We appreciate all that Mr. Larry Ellison has brought to the game of tennis. And, we are even more appreciative of the players who make tennis great, from Serena Williams and Victoria Azarenka to Roger Federer and Rafael Nadal. We are also excited about some of the up and coming players like Coco Vandeweghe and Andrea Hlavackova, whom we are proudly sponsoring. With this announcement, we look forward to supporting BNP Paribas Open in 2017.”
BNP Paribas Open is an annual tennis tournament held in Indian Wells, California. The tournament is a Masters 1000 event on the men’s tour and a Premier Mandatory event on the women’s tour. This is one of the best attended tennis tournament with over 450,000 visitors during the event and 18,000,000 viewers.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo technology. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.